Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Anji: a new wrinkle on asset-centric development

Emerging Company Profile: Anji tests ‘dynamic equity’ model, sharing programs’ ownership with originators via JVs

September 28, 2021 10:59 PM UTC

Using a business model centering on joint ventures, three-year-old Anji will test whether its “dynamic equity” in-licensing approach will create sufficient value to appeal to more biopharma programs’ originators.

Anji Pharmaceuticals Inc. said Tuesday it had raised $70 million from a single investor, China-based CR Capital, that will help it fund two clinical programs. Anji is advancing ANJ900, a gut-targeted formulation of metformin for Type II diabetes, in the Phase III DREAM-T2D study; and ANJ908, a DGAT1 inhibitor in Phase II testing for chronic idiopathic constipation...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article